Summit Therapeutics announced it has received a Fast Track designation from the Food and Drug Administration (FDA) for Ezutromid in the treatment of Duchenne muscular dystrophy (DMD).
DMD is a progressive muscle wasting disease that affects males across the world. It is caused by various genetic faults in the gene that encodes dystrophin, a protein needed for healthy function of all muscles.
The Fast Track process facilitates the development and expedites the review of drugs to treat serious conditions that address an unmet need. Ezutromid, an oral utrophin modulator, has also been granted Orphan Drug designation by the FDA. This small molecule candidate is believed to potentially slow down or even stop the progression of DMD regardless of the underlying gene mutation.
For more information visit Summitplc.com.